The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 27, 2019
Filed:
Jun. 01, 2017
Applicant:
University of Virginia Patent Foundation, Charlottesville, VA (US);
Inventor:
Gordon W. Laurie, Charlottesville, VA (US);
Assignee:
University of Virginia Patent Foundation, Charlottesville, VA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/18 (2006.01); G01N 33/68 (2006.01); C07K 14/475 (2006.01); G01N 33/573 (2006.01); A61K 9/00 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6893 (2013.01); A61K 9/0048 (2013.01); A61K 38/1709 (2013.01); A61K 38/18 (2013.01); C07K 14/475 (2013.01); C12Y 302/01166 (2013.01); G01N 33/573 (2013.01); G01N 33/68 (2013.01); G01N 2333/4706 (2013.01); G01N 2333/4722 (2013.01); G01N 2333/4728 (2013.01); G01N 2333/70596 (2013.01); G01N 2333/924 (2013.01); G01N 2800/16 (2013.01); G01N 2800/162 (2013.01);
Abstract
The present invention provides compositions and methods for identifying subjects suffering from dry eye that can be treated by topical administration of a composition comprising lacritin or a bioactive fragment thereof. The application discloses in part that a ˜90 KDa deglycanated form of syndecan-1 is abundant in tears of normal individuals but not individuals suffering from dry eye, whereas a ˜25 kDa syndecan-1 fragment is detectable in dry, but not normal tears.